Cronometer, a leader in nutrition and health tracking, is proud to announce the integration of Continuous Glucose Monitors (CGMs) with its innovative platform. This feature provides users with the ...

Can epilepsy be prevented in future generations? While genetics play a role, experts believe advances in gene editing, ...

Vita, a decanoic acid-enriched medical food, to children with Dravet syndrome or early-onset genetic epilepsy and adults with refractory epilepsy. K. Vita contained 98.5% MCTs, with C10 constituting ...

Biogen ( NASDAQ: BIIB) and Stoke Therapeutics ( NASDAQ: STOK) said on Tuesday they are collaborating to develop and ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...

Study: Neonatal but not Juvenile Gene Therapy Reduces Seizures and Prolongs Lifespan in SCN1B-Dravet Syndrome Mice. Image Credit: Natali _ Mis/Shutterstock.com Developmental and epileptic ...

Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage ...

Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.

Existing treatments for Dravet include Jazz Pharmaceuticals’ Epidiolex and UCB’s Fintepla, but none of the approved products address the underlying genetic cause of the syndrome. Similarly ...